KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Halozyme Therapeutics (HALO) over the last 16 years, with Q4 2025 value amounting to $217.6 million.

  • Halozyme Therapeutics' Free Cash Flow rose 2404.98% to $217.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $644.6 million, marking a year-over-year increase of 3762.43%. This contributed to the annual value of $644.6 million for FY2025, which is 3762.43% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Free Cash Flow of $217.6 million as of Q4 2025, which was up 2404.98% from $175.6 million recorded in Q3 2025.
  • Halozyme Therapeutics' 5-year Free Cash Flow high stood at $217.6 million for Q4 2025, and its period low was $36.4 million during Q2 2021.
  • Moreover, its 5-year median value for Free Cash Flow was $90.3 million (2021), whereas its average is $100.9 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Free Cash Flow skyrocketed by 195218.35% in 2021 and then crashed by 4339.71% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Free Cash Flow stood at $82.4 million in 2021, then dropped by 4.45% to $78.7 million in 2022, then grew by 26.77% to $99.8 million in 2023, then skyrocketed by 75.84% to $175.4 million in 2024, then grew by 24.05% to $217.6 million in 2025.
  • Its Free Cash Flow was $217.6 million in Q4 2025, compared to $175.6 million in Q3 2025 and $98.1 million in Q2 2025.